Related references
Note: Only part of the references are listed.A review of glioblastoma immunotherapy
Ravi Medikonda et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Rationally designed drug delivery systems for the local treatment of resected glioblastoma
Chiara Bastiancich et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer
Debra Wu et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2021)
Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy
Hyunmin Chung et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Immunogenic Cell Death Induced by Chemoradiotherapy of Novel pH-Sensitive Cargo-Loaded Polymersomes in Glioblastoma
Chen He et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma
Roxanne Wouters et al.
CANCERS (2021)
Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma
Ketao Jin et al.
CANCERS (2021)
Myeloid Cells in Glioblastoma Microenvironment
Alessandra De Leo et al.
CELLS (2021)
Biocompatible copolymer formulations to treat glioblastoma multiforme
Luiza C. S. Erthal et al.
ACTA BIOMATERIALIA (2021)
ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma
Natasha D. Sheybani et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Combination immunotherapy strategies for glioblastoma
Hok Yee Chan et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection
Jing Zhang et al.
NATURE NANOTECHNOLOGY (2021)
Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
Thamiris Becker Scheffel et al.
FRONTIERS IN ONCOLOGY (2021)
Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
Kelsey Maddison et al.
Oncotarget (2021)
Targeting Innate Immunity in Cancer Therapy
Srikrishnan Rameshbabu et al.
VACCINES (2021)
Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells
Timo Burster et al.
PHARMACEUTICALS (2021)
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
Masmudur M. Rahman et al.
CANCERS (2021)
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
Elena V. Abakushina et al.
VACCINES (2021)
Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction
Jianye Xu et al.
CELL DEATH & DISEASE (2021)
Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies
Giuseppe Nicolo Fanelli et al.
GENES (2021)
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution
Zhaoshi Bao et al.
FRONTIERS OF MEDICINE (2021)
STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer
Jiaqi Shi et al.
CELLULAR IMMUNOLOGY (2021)
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Fan Yang et al.
NATURE COMMUNICATIONS (2021)
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Takashi Nakamura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
STING Agonists as Cancer Therapeutics
Afsaneh Amouzegar et al.
CANCERS (2021)
Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy
Rikke Sick Andersen et al.
CANCERS (2021)
Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors
Daniele E. Mascarelli et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Therapeutic cancer vaccines
Mansi Saxena et al.
NATURE REVIEWS CANCER (2021)
Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models
Weijun Wang et al.
JOURNAL OF NEUROSURGERY (2020)
Insights in the immunobiology of glioblastoma
Dimitrios Strepkos et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2020)
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
Julio Enriquez Perez et al.
BMC CANCER (2020)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Sangeeta Goswami et al.
NATURE MEDICINE (2020)
Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine
Connor J. Liu et al.
NEURO-ONCOLOGY (2020)
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto et al.
TRANSLATIONAL ONCOLOGY (2020)
Blockade of CD73 delays glioblastoma growth by modulating the immune environment
J. H. Azambuja et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
Stephanie Sanders et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Role of Selected Chemokines and Their Receptors in the Development of Gliomas
Magdalena Groblewska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Alexander H. Morrison et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
Christina A. von Roemeling et al.
NATURE COMMUNICATIONS (2020)
Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
Helene Gregoire et al.
FRONTIERS IN PHARMACOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner
Marine M. Leblond et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Immunotherapies and Combination Strategies for Immuno-Oncology
Cody Barbari et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
Iris Y. Sheng et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration
Martina Ott et al.
JCI INSIGHT (2020)
Polymorphonuclear myeloid-derived suppressor cells limit antigen cross- presentation by dendritic cells in cancer
Alessio Ugolini et al.
JCI INSIGHT (2020)
Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types
Jasneet Kaur Khalsa et al.
NATURE COMMUNICATIONS (2020)
GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
Victoria E. Sanchez et al.
SCIENTIFIC REPORTS (2020)
Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma
Kenji Shono et al.
SCIENTIFIC REPORTS (2020)
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Joshua R. D. Pearson et al.
FRONTIERS IN IMMUNOLOGY (2020)
TIGIT in cancer immunotherapy
Joe-Marc Chauvin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome
Brij S. Karmur et al.
FRONTIERS IN ONCOLOGY (2020)
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
Na Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
Jinyang Hu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Blood-Brain Barrier Modulation to Improve Glioma Drug Delivery
Huilong Luo et al.
PHARMACEUTICS (2020)
Bacillus Calmette-Guerin (BCG) Therapy for Bladder Cancer: An Update
Sandra Guallar-Garrido et al.
IMMUNOTARGETS AND THERAPY (2020)
Brain immunology and immunotherapy in brain tumours
John H. Sampson et al.
NATURE REVIEWS CANCER (2020)
Immunotherapy in CNS cancers: the role of immune cell trafficking
Nivedita M. Ratnam et al.
NEURO-ONCOLOGY (2019)
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Sabrina Heynckes et al.
BMC CANCER (2019)
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Paul Lesueur et al.
BMC CANCER (2019)
Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
Jonathan B. Lamano et al.
CLINICAL CANCER RESEARCH (2019)
Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
Aida Karachi et al.
NEURO-ONCOLOGY (2019)
Dexamethasone in Glioblastoma Multiforme Therapy: Mechanisms and Controversies
Marta Cenciarini et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
Nusrat Jahan et al.
ONCOIMMUNOLOGY (2019)
Turning the corner on therapeutic cancer vaccines
Robert E. Hollingsworth et al.
NPJ VACCINES (2019)
Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments
Sally L. Perrin et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
Cancer Vaccines
Peter J. DeMaria et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment
Adela Wu et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling
Angela Yan et al.
JOURNAL OF NEUROSCIENCE (2019)
Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors
D. M. Abarca-Merlin et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma
Erlend Skaga et al.
BMC CANCER (2019)
A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications
Xiaolin Fan et al.
FRONTIERS OF MEDICINE (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity
Aurobind Vidyarthi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
PD-L1/PD-1 Axis in Glioblastoma Multiforme
Jakub Litak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials
Franciele Aline Bruinsmann et al.
MOLECULES (2019)
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
Mariangela Di Tacchio et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides
Kavisha R. Ulapane et al.
PHARMACEUTICS (2019)
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study
Todd Mainprize et al.
SCIENTIFIC REPORTS (2019)
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity
Hayley S. Ma et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma
Junseong Park et al.
ONCOIMMUNOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype
M. D. Sorensen et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2018)
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model
Bailing Dai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Cellular origin of glioblastoma and its implication in precision therapy
Maojin Yao et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Karolina Woroniecka et al.
CLINICAL CANCER RESEARCH (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Nivolumab plus ipilimumab in metastatic colorectal cancer
Elizabeth Gourd
LANCET ONCOLOGY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Multidimensional communication in the microenvirons of glioblastoma
Marike L. Broekman et al.
NATURE REVIEWS NEUROLOGY (2018)
WHO 2016 Classification of gliomas
P. Wesseling et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
CNS cancer immunity cycle and strategies to target this for glioblastoma
Malaka Ameratunga et al.
Oncotarget (2018)
Next generation immune-checkpoints for cancer therapy
Chiara Donini et al.
JOURNAL OF THORACIC DISEASE (2018)
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Alice L. Hung et al.
ONCOIMMUNOLOGY (2018)
Beyond the Blood: Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma
Katherine Elizabeth Warren
FRONTIERS IN ONCOLOGY (2018)
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
Martina Da Ros et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Combining immune Checkpoint inhibitors with Conventional Cancer Therapy
Yiyi Yan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
Vassilis Genoud et al.
ONCOIMMUNOLOGY (2018)
Microglia and macrophages in brain homeostasis and disease
Qingyun Li et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Immunotherapy Approaches in the Treatment of Malignant Brain Tumors
Anastasie M. Dunn-Pirio et al.
CANCER (2017)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
An immunocompetent mouse model of human glioblastoma
Samantha Semenkow et al.
ONCOTARGET (2017)
Immune Checkpoint in Glioblastoma: Promising and Challenging
Jing Huang et al.
FRONTIERS IN PHARMACOLOGY (2017)
In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment
Guranda Chitadze et al.
ONCOIMMUNOLOGY (2017)
Engineering challenges for brain tumor immunotherapy
Johnathan G. Lyon et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha et al.
CANCER CELL (2017)
US FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2017)
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Zhihong Chen et al.
CANCER RESEARCH (2017)
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet
Gabriele D'Errico et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells
Alan L. Chang et al.
CANCER RESEARCH (2016)
CSF, blood-brain barrier, and brain drug delivery
William M. Pardridge
EXPERT OPINION ON DRUG DELIVERY (2016)
Origin, fate and dynamics of macrophages at central nervous system interfaces
Tobias Goldmann et al.
NATURE IMMUNOLOGY (2016)
The role of microglia and macrophages in glioma maintenance and progression
Dolores Hambardzumyan et al.
NATURE NEUROSCIENCE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
Dickran Kazandjian et al.
ONCOLOGIST (2016)
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
Mira A. Patel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Konrad Gabrusiewicz et al.
JCI INSIGHT (2016)
Increased proportion of FoxP3+regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
Elias J. Sayour et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The role of checkpoints in the treatment of GBM
Jennifer E. Kim et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
The CD40/CD40L axis in glioma progression and therapy
Paul R. Walker et al.
NEURO-ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Glioma-Associated Microglia/Macrophages Display an Expression Profile Different from M1 and M2 Polarization and Highly Express Gpnmb and Spp1
Frank Szulzewsky et al.
PLOS ONE (2015)
Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry
Haiming Luo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Anatomy and physiology of the blood-brain barrier
Yonatan Serlin et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
Revisiting the Mechanisms of CNS Immune Privilege
Antoine Louyeau et al.
TRENDS IN IMMUNOLOGY (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant Glioma Following Local Administration
Elizabeth Nance et al.
ACS NANO (2014)
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Stupp et al.
ANNALS OF ONCOLOGY (2014)
Glioblastoma: From Molecular Pathology to Targeted Treatment
Timothy F. Cloughesy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
Thermoreversible Poly(ethylene glycol)-g-Chitosan Hydrogel as a Therapeutic T Lymphocyte Depot for Localized Glioblastoma Immunotherapy
Ching-Ting Tsao et al.
BIOMACROMOLECULES (2014)
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells
Akemi Kosaka et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
Patrick L. Raber et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Mouse glioma immunotherapy mediated by A2B5+GL261 cell lysate-pulsed dendritic cells
Ming Xu et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
Zineb Belcaid et al.
PLOS ONE (2014)
Modulation of A(1) and A(2B) adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy
S. Daniele et al.
CELL DEATH & DISEASE (2014)
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Sara Fritzell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers
Michael Prosniak et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells
Claudia Quezada et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level
Justyna Kmiecik et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck et al.
NATURE MEDICINE (2013)
Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways
Katrin Kierdorf et al.
NATURE NEUROSCIENCE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
Tooba A. Cheema et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling
Salvatore J. Coniglio et al.
MOLECULAR MEDICINE (2012)
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006
K. Robin Yabroff et al.
NEURO-ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells
Christian Schulz et al.
SCIENCE (2012)
A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain Tissue
Elizabeth A. Nance et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman et al.
CLINICAL CANCER RESEARCH (2011)
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration
Marco Prinz et al.
NATURE NEUROSCIENCE (2011)
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice
Mitomu Kioi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Florent Ginhoux et al.
SCIENCE (2010)
Development of a novel mouse glioma model using lentiviral vectors
Tomotoshi Marumoto et al.
NATURE MEDICINE (2009)
The use of GEM models for experimental cancer therapeutics
Aarthi Gopinathan et al.
DISEASE MODELS & MECHANISMS (2008)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
CNS immune privilege: hiding in plain sight
Monica J. Carson et al.
IMMUNOLOGICAL REVIEWS (2006)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
B Huang et al.
CANCER RESEARCH (2006)
B7-homolog I expression by human glioma: a new mechanism of immune evasion
R Wilmotte et al.
NEUROREPORT (2005)
CD40 ligation activates murine macrophages via an IFN-γ-dependent mechanism resulting in tumor cell destruction in vitro
IN Buhtoiarov et al.
JOURNAL OF IMMUNOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations
S Ronchetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas
M Platten et al.
ANNALS OF NEUROLOGY (2003)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2002)
Share Paper
